DETAILED NOTES ON HEMGENIX

Variety of qualified sufferers: CDEC reviewed the uncertainty in the volume of sufferers with moderately intense to severe hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some patients who will be categorised as obtaining moderate or moderate sickness could have a critical